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Rivaroxaban is a direct oral anticoagulant (DOAC) approved as an important alternative to warfarin in patients with nonvalvular
atrial ﬁbrillation. We report the case of an 87-year-old man with past medical history of nonvalvular atrial ﬁbrillation on
rivaroxaban and recently started amiodarone for pulseless ventricular tachycardia who presented to our hospital with
intermittent chest pain and was diagnosed with spontaneous hemopericardium causing cardiac tamponade. The culprit drugs
were discontinued, and the patient was treated with emergent pericardiocentesis. Both rivaroxaban and amiodarone are
substrates for the CYP3A4 hepatic pathway, and concomitant use can result in increased plasma rivaroxaban levels causing an
increased propensity to bleeding. While most physicians are cognizant of the need for renal dosing of rivaroxaban, this article
aims to increase awareness of its interactions with drugs that are also metabolized through the same hepatic CYP450 pathway.

1. Background
Rivaroxaban is a direct oral anticoagulant approved by the
United States Food and Drug Administration (FDA) for
stroke prevention in nonvalvular atrial ﬁbrillation [1]. Amiodarone is an antiarrhythmic agent indicated for the prevention of recurrent life-threatening ventricular arrhythmias
[2]. All anticoagulants including rivaroxaban are associated
with increased risk of bleeding. The risk of bleeding with
rivaroxaban can be accentuated by the concomitant use of
medications such as amiodarone [3] which compete for
metabolism via the CYP3A4 hepatic pathway [4]. The incidence of spontaneous hemopericardium due to rivaroxaban
is unknown, likely due to its rarity as only few cases have
been documented so far [5–7]. However, with increasing
use of this medication, rare side eﬀects like this will be
encountered more often. Clinicians must be aware of this
rare catastrophic possibility that could result from the
lethal combination of rivaroxaban and amiodarone. We suggest that rivaroxaban package insert should include more

information on medications considered to be inhibitors of
CYP3A4 and P-glycoprotein system.

2. Case Presentation
An 87-year-old male with medical history of paroxysmal
atrial ﬁbrillation on 20 mg of rivaroxaban daily, recent pulseless ventricular tachycardia with implantable cardiac deﬁbrillator in situ, and nonischemic cardiomyopathy (ejection
fraction 35%) presented to the emergency room (ER) with
intermittent chest pain and light headedness of 2 days
duration. Chest pain was exertional, left sided, and pleuritic. He also reported shortness of breath but denied cough,
fever, or any other infectious. Of note, he was commenced
on 200 mg amiodarone daily four months prior to presentation following an episode of syncope due to pulseless
ventricular tachycardia.
Initial vital signs showed blood pressure of 89/60 mmHg
with pulse rate of 59/min, temperature of 98.2°F, and respiratory rate of 14 breaths/min with normal oxygen saturation of
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Figure 1: Electrocardiogram showing diﬀuse ST segment elevation with low voltage QRS complexes.

100% on ambient air. On physical examination, he was in
no acute distress and was alert and oriented to time, place,
and person. Jugular venous distention was noted on neck
examination. Heart sounds were muﬄed, but lung ﬁelds
were clear to auscultation. Peripheral pulses were also weak
but palpable.

3. Investigations
His EKG on arrival to the emergency room showed new widespread ST segment elevation (Figure 1). His troponin was
trended and remained <0.03 ng/mL (normal <0.05 ng/mL).
Complete blood count showed hemoglobin of 11.2 g/dL
(normal 14–17.5 g/dL), white blood cell count of 11.7/
microliter (normal 4.8–10.8/microliter), and normal platelet
count of 211/microliter (normal 130–400/microliter). Basic
metabolic panel revealed creatinine of 3.4 mg/dL from
baseline of <0.8 mg/dL (normal 0.6–1.3 mg/dL) with BUN
of 58 mg/dL (normal 7–25 mg/dL). His liver function test
showed AST of 90 U/L (normal 13–39 U/L), ALT of 126 U/L
(normal 7–52 U/L), and total bilirubin of 1.2 mg/dL (0.3–
1.0 mg/dL). INR was also elevated at 2.2 (normal 0.9–1.1) with
prothrombin time of 24.7 seconds (normal 12.3–14.6 seconds). Initial lactate was also elevated at 3.2 meq/L (normal
0.6–1.4 meq/L).
Chest X-ray revealed enlargement of the cardiomedistinal silhouette. CT chest revealed new moderate-sized pericardial eﬀusion (Figure 2).
Transthoracic echocardiogram (TTE) revealed large
circumferential pericardial eﬀusion and evidence for tamponade physiology with multichamber collapse and significant respirophasic variation to the mitral inﬂow pattern
(Figure 3). Please see Supplementary Material (available here).

Figure 2: Chest CT scan (transverse view) showing ﬂuid in the
pericardial space.

Figure 3: Parasternal long axis view of transthoracic echocardiogram
showing ﬂuid within the pericardial space.
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4. Differential Diagnosis
Given the patient’s history of intermittent chest pain and
presence of ST segment elevation on EKG, our initial suspicion was an ST segment elevation myocardial infarction.
However, at the time of evaluation by the cardiologist, the
patient had no chest pain and serial troponin levels remained
normal. Notably, patient had coronary angiography done 9
months prior to index presentation revealed minimal plaquing of the coronary arteries. We now know that the hypotension, muﬄed heart sounds, and jugular venous distention
were part of the Beck’s triad of cardiac tamponade. The lactic
acidosis, acute kidney injury, and elevated liver enzymes were
likely the result of tissue hypoperfusion from hypotension
while the leucocytosis was likely reactive.

5. Treatment
Based on the initial ﬁnding of ST segment elevation on EKG,
he received a loading dose of 324 mg of ASA by EMS. Amiodarone was discontinued due to deranged liver and renal
functions. We also held his rivaroxaban due to abnormal
clotting proﬁle and ﬁnding of hemopericardium on imaging
studies. He had urgent pericardiocentesis in the catheterization laboratory with initial drainage of 825 mLs of sanguinous ﬂuid, and postprocedural TTE showed evidence of
resolution of tamponade. The pericardiocentesis catheter
was left in place to drain any residual collections, and patient
was transferred to the intensive care unit. He had daily TTE
at the bedside, and his pericardial drainage volume progressively reduced from 160 cc on day 1 to 100 cc on day 2 to
80 cc on day 3 postpericardiocentesis when the drain was
removed. Pericardial ﬂuid analysis was negative for organisms or malignancy.

6. Outcome and Follow-Up
Our patient experienced signiﬁcant improvement of his
symptoms following pericardiocentesis. His blood pressure
normalized, and IV dopamine was discontinued immediately
after pericardiocentesis. His renal function also improved
signiﬁcantly evidenced by a reduction in creatinine to normal
at the time of discharge. He went home 5 days after admission and was instructed to stop his amiodarone and rivaroxaban in the mean time until his oﬃce appointment with
his cardiologist.
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rivaroxaban in our patient resulting in nontraumatic hemopericardium and eventual cardiac tamponade.
Elimination of rivaroxaban occurs through a dual
pathway—hepatic metabolism occurs via the CYP450 pathway
(mainly by CYP3A4 and CYP2J2) while renal excretion
via P-glycoprotein-mediated secretion [4]. Amiodarone
and its main metabolite N-desethylamiodarone (NDEA)
inhibit CYP3A4 and P-glycoprotein resulting in supratherapeutic concentrations of rivaroxaban when used simultaneously.
When used for stroke prophylaxis in patients with
nonvalvular atrial ﬁbrillation, clinical trials evaluating the
safety and eﬃcacy of rivaroxaban using the cockroft-gault
formula recommend that for creatinine clearance greater
than 50 mL/minute as was the case in our patient prior
to this admission, a standard dose of 20 mg once daily is adequate. However, for CrCl between 15 and 50 mL/minute, a
dose adjustment to 15 mg once daily may be considered.
Most clinicians recommend discontinuing rivaroxaban in
acute kidney injury or CrCl less than 15 mL/minute [9]. No
guidelines exist for dose adjustment when used with other
medications undergoing CYP450 metabolism.
Andexanet alfa, a recombinant modiﬁed human factor Xa
protein, is an antidote recently approved by the United States
Food and Drug Administration (FDA) [10] for patients
treated with rivaroxaban and apixaban when reversal of
anticoagulation is needed for life-threatening bleeding [11].
However, there are neither routinely available laboratory
tests to measure the anticoagulant eﬀect of rivaroxaban nor
consensus guidelines on the use of prothrombin complex concentrates, recombinant factor VIIa, and the newly approved
reversal agents in patients on direct oral anticoagulants.
This article aims to alert clinicians to this rare but
increasingly reported side eﬀect of rivaroxaban. A high index
of suspicion is needed for recognition and diagnosis of spontaneous hemopericardium. Caution should be observed especially in elderly patients with declining renal function and
increased likelihood of polypharmacy. With increasing use
of rivaroxaban and other novel anticoagulants and the recent
approval of a new reversal agent, more research is needed to
develop monitoring laboratory parameters to determine and
monitor their therapeutic range.
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7. Discussion
Based on the Naranjo causality assessment scale [8], there is
probable relationship between our patient’s spontaneous
hemopericardium and rivaroxaban use.
Serious bleeding events have been reported with rivaroxaban, mainly intracranial and gastrointestinal [9], but only a
few case reports of nontraumatic hemopericardium exist.
Altered hepatic metabolism resulting from coadministration with amiodarone and transient renal impairment
synergistically resulted in supratherapeutic serum levels of

Parasternal long axis view of transthoracic echocardiogram
showing large circumferential pericardial eﬀusion with evidence for tamponade physiology. (Supplementary Materials)
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